Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SWOG 2107
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
- NCT05308446 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on SWOG 2107 (cetuximab, encorafenib and 1 more in Metastatic Colon Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG 2107 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 6 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Colon Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma
- Interventions
- Cetuximab; Encorafenib; Nivolumab
- Arms
- Arm I (encorafenib, cetuximab, nivolumab) · Experimental
- Arm II (encorafenib, cetuximab) · Active comparator
- Enrollment
- 86
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 19, 2022
- Primary completion
- Feb 28, 2026
- Results posted
- No
- Registry record
- NCT05308446 · updated Jul 8, 2026